OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Expression of Histone Deacetylases in Diffuse Large B-cell Lymphoma and Its Clinical Significance
Sung Hak Lee, Changyoung Yoo, Soyoung Im, et al.
International Journal of Medical Sciences (2014) Vol. 11, Iss. 10, pp. 994-1000
Open Access | Times Cited: 31
Sung Hak Lee, Changyoung Yoo, Soyoung Im, et al.
International Journal of Medical Sciences (2014) Vol. 11, Iss. 10, pp. 994-1000
Open Access | Times Cited: 31
Showing 1-25 of 31 citing articles:
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Yixuan Li, Edward Seto
Cold Spring Harbor Perspectives in Medicine (2016) Vol. 6, Iss. 10, pp. a026831-a026831
Open Access | Times Cited: 1038
Yixuan Li, Edward Seto
Cold Spring Harbor Perspectives in Medicine (2016) Vol. 6, Iss. 10, pp. a026831-a026831
Open Access | Times Cited: 1038
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies
Ailin Zhao, Hui Zhou, Jinrong Yang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 62
Ailin Zhao, Hui Zhou, Jinrong Yang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 62
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
Xiaoguang Wang, Brittany C. Waschke, Rachel A. Woolaver, et al.
Protein & Cell (2020) Vol. 11, Iss. 7, pp. 472-482
Open Access | Times Cited: 81
Xiaoguang Wang, Brittany C. Waschke, Rachel A. Woolaver, et al.
Protein & Cell (2020) Vol. 11, Iss. 7, pp. 472-482
Open Access | Times Cited: 81
Histone modifications: A review about the presence of this epigenetic phenomenon in carcinogenesis
Emanuely Silva Chrun, Filipe Modolo, Filipe Ivan Daniel
Pathology - Research and Practice (2017) Vol. 213, Iss. 11, pp. 1329-1339
Closed Access | Times Cited: 80
Emanuely Silva Chrun, Filipe Modolo, Filipe Ivan Daniel
Pathology - Research and Practice (2017) Vol. 213, Iss. 11, pp. 1329-1339
Closed Access | Times Cited: 80
Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas
Xiaoguang Wang, Brittany C. Waschke, Rachel A. Woolaver, et al.
Cancer Immunology Research (2019) Vol. 7, Iss. 8, pp. 1318-1331
Open Access | Times Cited: 61
Xiaoguang Wang, Brittany C. Waschke, Rachel A. Woolaver, et al.
Cancer Immunology Research (2019) Vol. 7, Iss. 8, pp. 1318-1331
Open Access | Times Cited: 61
Recent advancement of HDAC inhibitors against breast cancer
Syed Abdulla Mehmood, Kantrol Kumar Sahu, Sounok Sengupta, et al.
Medical Oncology (2023) Vol. 40, Iss. 7
Closed Access | Times Cited: 17
Syed Abdulla Mehmood, Kantrol Kumar Sahu, Sounok Sengupta, et al.
Medical Oncology (2023) Vol. 40, Iss. 7
Closed Access | Times Cited: 17
Characterization of hepatitis B virus infection and viral DNA integration in non‐Hodgkin lymphoma
Mengge Li, Yuling Shen, Yi‐Ming Chen, et al.
International Journal of Cancer (2020) Vol. 147, Iss. 8, pp. 2199-2209
Open Access | Times Cited: 36
Mengge Li, Yuling Shen, Yi‐Ming Chen, et al.
International Journal of Cancer (2020) Vol. 147, Iss. 8, pp. 2199-2209
Open Access | Times Cited: 36
HDAC inhibitors: Promising agents for leukemia treatment
Yun Deng, Cheng Qian, Jing He
Biochemical and Biophysical Research Communications (2023) Vol. 680, pp. 61-72
Closed Access | Times Cited: 11
Yun Deng, Cheng Qian, Jing He
Biochemical and Biophysical Research Communications (2023) Vol. 680, pp. 61-72
Closed Access | Times Cited: 11
Recent Advancements in the Development of HDAC/Tubulin Dual-Targeting Inhibitors
Christine Tran, Abdallah Hamzé
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 341-341
Open Access
Christine Tran, Abdallah Hamzé
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 341-341
Open Access
Epigenetic Symphony in Diffuse Large B-Cell Lymphoma: Orchestrating the Tumor Microenvironment
Andreea Daniela Gheorghe, Miruna Cristian, Eliza Calin, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 853-853
Open Access
Andreea Daniela Gheorghe, Miruna Cristian, Eliza Calin, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 853-853
Open Access
Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response
Afua A. Mensah, Ivo Kwee, Eugenio Gaudio, et al.
Oncotarget (2014) Vol. 6, Iss. 7, pp. 5059-5071
Open Access | Times Cited: 32
Afua A. Mensah, Ivo Kwee, Eugenio Gaudio, et al.
Oncotarget (2014) Vol. 6, Iss. 7, pp. 5059-5071
Open Access | Times Cited: 32
How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot
Mandy Beyer, Nicole Kiweler, Siavosh Mahboobi, et al.
Methods in molecular biology (2016), pp. 355-364
Closed Access | Times Cited: 27
Mandy Beyer, Nicole Kiweler, Siavosh Mahboobi, et al.
Methods in molecular biology (2016), pp. 355-364
Closed Access | Times Cited: 27
Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics
Cui Hao, Qianqian Hong, Ran Wei, et al.
European Journal of Medicinal Chemistry (2021) Vol. 229, pp. 114049-114049
Closed Access | Times Cited: 20
Cui Hao, Qianqian Hong, Ran Wei, et al.
European Journal of Medicinal Chemistry (2021) Vol. 229, pp. 114049-114049
Closed Access | Times Cited: 20
Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway
Hongwei Zhang, Fenqing Chi, Keru Qin, et al.
Molecular Medicine Reports (2021) Vol. 23, Iss. 5
Open Access | Times Cited: 19
Hongwei Zhang, Fenqing Chi, Keru Qin, et al.
Molecular Medicine Reports (2021) Vol. 23, Iss. 5
Open Access | Times Cited: 19
Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B‐cell lymphoma
Zebing Liu, Ying Cai, Yu Yang, et al.
The Journal of Pathology (2018) Vol. 246, Iss. 2, pp. 141-153
Open Access | Times Cited: 22
Zebing Liu, Ying Cai, Yu Yang, et al.
The Journal of Pathology (2018) Vol. 246, Iss. 2, pp. 141-153
Open Access | Times Cited: 22
Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism
Xinyao Li, Zhengchang He, Bingqing Cheng, et al.
Cancer Biology & Therapy (2018) Vol. 19, Iss. 9, pp. 825-834
Open Access | Times Cited: 21
Xinyao Li, Zhengchang He, Bingqing Cheng, et al.
Cancer Biology & Therapy (2018) Vol. 19, Iss. 9, pp. 825-834
Open Access | Times Cited: 21
Alterations of Histone Modifications in Cancer
Amir Hosseini, Saverio Minucci
Elsevier eBooks (2018), pp. 141-217
Closed Access | Times Cited: 17
Amir Hosseini, Saverio Minucci
Elsevier eBooks (2018), pp. 141-217
Closed Access | Times Cited: 17
The contributory roles of histone deacetylases (HDACs) in hematopoiesis regulation and possibilities for pharmacologic interventions in hematologic malignancies
Mahdieh Mehrpouri, Atieh Pourbagheri‐Sigaroodi, Davood Bashash
International Immunopharmacology (2021) Vol. 100, pp. 108114-108114
Closed Access | Times Cited: 14
Mahdieh Mehrpouri, Atieh Pourbagheri‐Sigaroodi, Davood Bashash
International Immunopharmacology (2021) Vol. 100, pp. 108114-108114
Closed Access | Times Cited: 14
Chidamide and Oxaliplatin Synergistically Inhibit Colorectal Cancer Growth by Regulating the RPS27A-MDM2-P53 Axis
Zhaopeng Li, Deyong Bu, Xiaobin Wang, et al.
OncoTargets and Therapy (2023) Vol. Volume 16, pp. 703-721
Open Access | Times Cited: 5
Zhaopeng Li, Deyong Bu, Xiaobin Wang, et al.
OncoTargets and Therapy (2023) Vol. Volume 16, pp. 703-721
Open Access | Times Cited: 5
Epigenetic profiles of elevated cell free circulating H3.1 nucleosomes as potential biomarkers for non-Hodgkin lymphoma
Priscilla Van den Ackerveken, Alison Lobbens, Dorian Pamart, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Priscilla Van den Ackerveken, Alison Lobbens, Dorian Pamart, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents
Mussa Yussuf Khamis, Hui-Pan Wu, Qin Ma, et al.
Bioorganic Chemistry (2021) Vol. 109, pp. 104754-104754
Closed Access | Times Cited: 11
Mussa Yussuf Khamis, Hui-Pan Wu, Qin Ma, et al.
Bioorganic Chemistry (2021) Vol. 109, pp. 104754-104754
Closed Access | Times Cited: 11
Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review
Romana Masnikosa, Zorica Cvetković, David Pirić
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 21, pp. 11384-11384
Open Access | Times Cited: 1
Romana Masnikosa, Zorica Cvetković, David Pirić
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 21, pp. 11384-11384
Open Access | Times Cited: 1
Advances in epigenetic therapies for B-cell non-hodgkin lymphoma
Wei‐Wen Hu, Lanlan Zang, Xiaoxi Feng, et al.
Annals of Hematology (2024)
Closed Access | Times Cited: 1
Wei‐Wen Hu, Lanlan Zang, Xiaoxi Feng, et al.
Annals of Hematology (2024)
Closed Access | Times Cited: 1
Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma
Mingyang Wang, Xiaosheng Fang, Xin Wang
Leukemia & lymphoma/Leukemia and lymphoma (2019) Vol. 61, Iss. 4, pp. 763-775
Closed Access | Times Cited: 11
Mingyang Wang, Xiaosheng Fang, Xin Wang
Leukemia & lymphoma/Leukemia and lymphoma (2019) Vol. 61, Iss. 4, pp. 763-775
Closed Access | Times Cited: 11
Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies
Jia Yang, Dengwen Li, Jun Zhou
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 10
Jia Yang, Dengwen Li, Jun Zhou
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 10
